Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells (original) (raw)

• Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263–267.
  Article CAS PubMed Google Scholar
• Sparacio S, Pfeiffer T, Schaal H, Bosch V . Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001; 3: 602–612.
  Article CAS PubMed Google Scholar
• Kaul M, Yu H, Ron Y, Dougherty JP . Regulated lentiviral packaging cell line devoid of most viral _cis_-acting sequences. Virology 1998; 249: 167–174.
  Article CAS PubMed Google Scholar
• Klages N, Zufferey R, Trono D . A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170–176.
  Article CAS PubMed Google Scholar
• Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ . Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811–816.
  CAS PubMed PubMed Central Google Scholar
• Kotsopoulou E et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839–4852.
  Article CAS PubMed PubMed Central Google Scholar
• Zufferey R et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875.
  Article CAS PubMed Google Scholar
• Ikeda Y et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21: 569–572.
  Article CAS PubMed Google Scholar
• Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220–2224.
  CAS PubMed PubMed Central Google Scholar
• Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430–7436.
  CAS PubMed PubMed Central Google Scholar
• Sommerfelt MA, Weiss RA . Receptor interference groups of 20 retroviruses plating on human cells. Virology 1990; 176: 58–69.
  Article CAS PubMed Google Scholar
• Uckert W et al. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum Gene Ther 2000; 11: 1005–1014.
  Article CAS PubMed Google Scholar
• Kelly PF et al. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206–1214.
  CAS PubMed Google Scholar
• Hanawa H et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242–251.
  Article CAS PubMed Google Scholar
• Blaese RM et al. T-lymphocyte directed gene therapy for ADA-SCID: initial trail results after 4 years. Science 1995; 270: 475–480.
  Article CAS PubMed Google Scholar
• Bordingnon C et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270: 470–475.
  Article Google Scholar
• Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–672.
  Article CAS PubMed Google Scholar
• Abonour R et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652–658.
  Article CAS PubMed Google Scholar
• Pinter A et al. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes. J Virol 1997; 71: 8073–8077.
  CAS PubMed PubMed Central Google Scholar
• Gliniak BC, Kozak SL, Jones RT, Kabat D . Disulfide bonding controls the processing of retroviral envelope glycoproteins. J Biol Chem 1991; 266: 22991–22997.
  CAS PubMed Google Scholar
• Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001–8007.
  CAS PubMed PubMed Central Google Scholar
• Christodoulopoulos I, Cannon PM . Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 2001; 75: 4129–4138.
  Article CAS PubMed PubMed Central Google Scholar
• Stitz J et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000; 273: 16–20.
  Article CAS PubMed Google Scholar
• Sandrin V et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823–832.
  Article CAS PubMed Google Scholar
• Marandin A et al. Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 1998; 9: 1497–1511.
  Article CAS PubMed Google Scholar
• Duisit G, Salvetti A, Moullier P, Cosset FL . Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999; 10: 189–200.
  Article CAS PubMed Google Scholar
• Takeuchi Y et al. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 1996; 379: 85–88.
  Article CAS PubMed Google Scholar
• DePolo NJ et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218–222.
  Article CAS PubMed Google Scholar
• Takeuchi Y et al. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J Virol 1997; 71: 6174–6178.
  CAS PubMed PubMed Central Google Scholar
• Welsh RM, O'Donnell CL, Reed DJ, Rother RP . Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72: 4650–4656.
  CAS PubMed PubMed Central Google Scholar
• Reiser J . Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Therapy 2000; 7: 910–913.
  Article CAS PubMed Google Scholar
• VandenDriessche T, Naldini L, Collen D, Chuah MK . Oncoretroviral and lentiviral vector-mediated gene therapy. Methods Enzymol 2002; 346: 573–589.
  Article CAS PubMed Google Scholar
• Cosset FL et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69: 6314–6322.
  CAS PubMed PubMed Central Google Scholar
• Slingsby JH et al. Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency. Hum Gene Ther 2000; 11: 1439–1451.
  Article CAS PubMed Google Scholar
• Arai T et al. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J Virol 1998; 72: 1115–1121.
  CAS PubMed PubMed Central Google Scholar
• Pinter A et al. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 1982; 116: 499–516.
  Article CAS PubMed Google Scholar